|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acute Renal Failure |

* Department of Nephrology and Intensive Care, San Bortolo Hospital, Vicenza, Italy; and
Section of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut
Address correspondence to: Dr. Claudio Ronco, Department of Nephrology, San Bortolo Hospital, Viale Rodolfi 37, 36100 Vicenza, Italy. Phone: +39-0444-753650; Fax: +39-0444-753973; E-mail: cronco{at}goldnet.it
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Although AKI is associated with a high risk for death, its epidemiology and outcome are not well determined, in part as a result of the lack of a standardized definition. More than 35 different definitions have been used in the literature, including one by Bellomo et al. (7), creating conflicting results and making comparisons difficult (8). A practical definition should be based on widely accepted foundations of pathophysiology, clinical behavior, response to treatment, histopathologic features, and prognosis. To define better AKI and its characteristics, the Acute Dialysis Quality Initiative (ADQI) developed a consensus definition for AKI, grading the severity of the disease from "risk" to "injury" to "failure" (Table 1) (9). Recently, a number of single-center studies evaluated the incidence and outcome of AKI using this classification (1014). It has not been assessed, however, in a multicenter setting. This study estimates the incidence of AKI in ICU patients in northeastern Italy, describes the clinical characteristics of patients with AKI and their outcomes on the basis of their RIFLE (RiskInjuryFailureLossESRD) category, and explores the relationship between the two components (serum creatinine and urine output) of the RIFLE criteria.
|
| Materials and Methods |
|---|
|
|
|---|
Study Population
Patients who were older than 18 yr and who were admitted to one of the participating ICU during the study period were considered for study inclusion. From this population, only incident patients who fulfilled criteria for the risk, injury, and failure categories of the RIFLE criteria for AKI were included in the study (9). Either the serum creatinine or urine output criterion was used to diagnose AKI and determine the RIFLE classification of each patient, using the criteria that led to the worst possible classification (Table 1). The RIFLE classification at the time of diagnosis of AKI (also called RIFLE "initial") was considered for analysis. For patients in whom baseline serum creatinine values were not known (22%), the value was estimated using the Modification of Diet in Renal Disease equation (assuming average baseline GFR of 75 ml/min per 1.73 m2), as recommended by the ADQI workgroup (9,15). Patients who had stage 5 chronic kidney disease and were undergoing long-term renal replacement therapy (RRT) were excluded from the study. Two patients were admitted twice to the ICU during the study period for different reasons; in each case, the second admission was counted as a new case.
Data Collection
Multiple data elements were prospectively collected on each patient with AKI at study inclusion and were recorded on a standardized case report form that was developed for this study, which was pilot-tested in one of the participating centers (Ospedale San Bortolo) before dissemination to the other study sites. Requested data included demographics, premorbid renal function, use of potentially nephrotoxic drugs, medical history, urine output, serum creatinine levels, and associated laboratory abnormalities at time of AKI diagnosis. For patients who were treated with RRT, we collected data regarding the initial and subsequent (if any) RRT modality, as well as the type of medical and nursing personnel who initiated and managed the therapy at bedside. Indications, frequency, duration, and operational characteristics of RRT were individualized for each patient by the treating physicians at each site. There were no prespecified criteria for initiation or withdrawal of RRT or for any of its aspects. ICU mortality was the primary outcome of interest. We also collected data on cause of death and ICU length of stay, as well as recovery of renal function, defined as a serum creatinine <1.5 mg/dl (133 µmol/L) and urine output >800 ml/d, or a return to baseline level of renal function at time of ICU discharge or death.
For calculation of the incidence of AKI, summary data on all ICU admissions from April to June 2003 were obtained from each participating center. This included the total number of admissions; frequency distribution of age, gender, and ICU length of stay for all ICU admissions; and the overall ICU mortality for that time period. Individual patient data were not available for patients without AKI.
Statistical Analyses
Continuous data are presented as the mean (95% confidence interval [CI]) or the median (interquartile range), as appropriate, and nominal data are presented as percentages. Comparisons among multiple groups were performed using the Fisher or the
2 test for nominal variables, and ANOVA (with Bonferroni correction) or Kruskal-Wallis test was used for numerical variables where appropriate. Kaplan-Meier survival analysis was used to compare 28-d ICU mortality among the RIFLE categories. Patients who were alive at ICU discharge were censored. The log-rank statistic was used to test differences between groups. Exploratory univariate analysis for several variables was performed to identify possible predictors of ICU mortality. P < 0.05 was considered as statistically significant. Serum creatinine levels and urine output were evaluated as both continuous variables (actual values and natural log) and dichotomous variables (above or below a particular level). Previous exposure to potentially nephrotoxic agents was explored in three different forms: "Angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers (ACEI/ARB) or nonsteroidal anti-inflammatory drugs," "ACEI/ARB and nonsteroidal anti-inflammatory drugs together," or "any nephrotoxic agent." The form "any nephrotoxic agent" had the strongest association with both mortality and need for RRT and was used for the final analysis.
Multivariable logistic regression analysis was then conducted to investigate independent predictors for ICU mortality and need for RRT. The analysis was conducted with backward stepwise method (exclusion probability 0.20; inclusion probability 0.10) for the following covariates: Age, sepsis, postsurgical cause of AKI, previous use of nephrotoxic agents, need for RRT, serum creatinine (natural log), and urine output (natural log). The model's goodness of fit was tested with the Hosmer-Lemeshow statistic. Agreement between the creatinine and urine output criteria of the RIFLE classification was evaluated with the
test. For exploration of the contribution of each criterion to the outcomes of interest, multivariable logistic regression analysis was repeated using the RIFLE class based on serum creatinine only (RIFLE-c) and again using the RIFLE class based on urine output only (RIFLE-o). Patients who failed to fulfill criteria for Rc or Ro are labeled as class 0c or 0o, respectively. All statistical analyses were performed using SPSS 11.5.1 (SPSS, Chicago, IL). A two-sided P < 0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
|
was 0.132 (P < 0.001).
|
Outcomes
Overall ICU mortality for all patients with AKI was 36.3% (95% CI 30.1 to 42.5%), significantly higher than that in the entire ICU cohort (P < 0.001). The top three reported causes of death were sepsis (35%), cardiac causes (12.8%), and pulmonary causes (4.7%). ICU mortality was highest among class F (49.5%), followed by class I (29.3%) then class R (20%). Kaplan-Meier survival analysis was statistically significant (P = 0.03 by log rank test; Figure 1). The results of the multivariate logistic regression analysis are shown in Table 5. RIFLE classification was the strongest predictor of ICU mortality. With respect to class R, the odds ratio (OR) was 2.2 for class I and 4.9 for class F (P = 0.01). Other variables that were associated with increased risk for ICU mortality were sepsis as the cause of AKI and need for RRT. A postsurgical cause for AKI, previous exposure to any nephrotoxic agent, higher serum creatinine, and urine output were associated with a lower risk for death. Mortality was not significantly different between patients with a prerenal cause of AKI (30 versus 39% [other cause of AKI]; P = 0.17). Thirty-six percent of patients with AKI recovered renal function at the time of death or ICU discharge. Recovery of renal function was seen more frequently among class R (57.8%) and I (43.9%) patients than among F patients (20.6%; P < 0.001). The median ICU length of stay for AKI survivors was 10 d (interquartile range 3 to 24 d), significantly longer than that of the entire ICU cohort (P < 0.001). ICU length of stay was not significantly different among the three RIFLE classes. The analysis was repeated using the RIFLE class only on the basis of serum creatinine criteria (RIFLE-c). With respect to class 0c, the OR was 3.0 (95% CI 0.2 to 38.3) for Rc, 7.3 (95% CI 0.6 to 88.7) for Ic, and 18.2 (95% CI 1.2 to 267.4) for Fc. However, when the analysis was performed with RIFLE class only on the basis of urine output criteria (RIFLE-o), it did not emerge as an independent predictor of mortality.
|
|
| Discussion |
|---|
|
|
|---|
Four retrospective, single-center studies have reported the use of the RIFLE classification in ICU patient populations (Table 6) (1013) and one in a general hospital population (14). The incidence of AKI in the ICU, that is, the aggregate of the R, I, and F categories, ranged from 19 to 67% (10,13), and the need for RRT ranged from 2.5 to 4.1% (10,11,13). In contrast to our study, in which we classified patients into RIFLE categories at time of diagnosis of AKI (RIFLE "initial"), others classified the patients on ICU admission (12), at peak creatinine levels (10), or maximum RIFLE class attained (13). Mortality, variably reported as hospital mortality, 30- or 90-d mortality, in class R ranged from 8 to 38.3%, in class I from 11.4 to 50%, and in class F from 26.3 to 74.4%. In all of these studies, mortality was, similar to our findings, significantly higher in class F. Kuitunen et al. (10) analyzed 813 consecutive cardiac surgery patients during an 8.5-mo period. Patients were classified into R, I, or F on the basis of the change between the preoperative and peak levels of plasma creatinine and urine output. Abosaif et al. (12) from the United Kingdom applied the RIFLE criteria to 183 ICU patients who had a serum creatinine level >1.7 mg/dl (150 µmol/L) and compared them with 24 control patients without AKI. They found a greater need for RRT in class F and noted a higher mortality as compared with our own and other studies, regardless of RIFLE class. ICU mortality in their F group was 74.4%. One possible explanation is that patients who already have AKI at the time of ICU admission have a poorer prognosis than those who develop AKI later in their ICU stay. The published literature is not clear on this issue. An earlier study from France showed delayed occurrence of AKI as an independent risk factor for mortality (6); however, a second French study did not find the same association (16). Bell et al. (11) studied 207 patients who were treated with CRRT in the ICU during a 6-yr period, 188 of whom were categorized into R, I, and F. The authors did not specifically state when the patients were classified. The remaining 16 patients were dialysis dependent before their ICU admission (considered as ESRD, RIFLE category E), and three were classified into the loss category. Being the only study that included exclusively patients who were treated with RRT, one would anticipate that this was a group with more advanced AKI and, therefore, a worse outcome. However, their mortality for all three categories was lower than that in the UK study (12) (Table 6). This may be due to a difference in case mix and center-specific practices regarding dialysis. It is possible that the Swedish center (11) may have been more aggressive in initiating RRT (criteria for CRRT not described), or patients with AKI on ICU admission have a worse prognosis. In the multivariate analysis in this study, only the RIFLE category, specifically class F, remained an independent predictor of mortality; class I had a mortality risk equal to that of class R (11). Recently, Hoste et al. (13) reported their experience with a large cohort of patients from seven ICU in a single center. In this retrospective study, they were also able to examine the progression from the initial RIFLE category to the maximum or peak RIFLE class attained by patients. They reported that more than half of R patients go on to progress to I or F, and more than one third of I patients progress to F. In terms of long-term follow-up, the Swedish study showed that only 4.8% of survivors were dialysis dependent at 6 mo (11); likewise, the UK study reported that survivors had significantly improved creatinine after 1 and 6 mo (12).
|
Aside from the RIFLE category, we noted that sepsis and need for RRT were independent predictors for ICU mortality. Sepsis and septic shock have been associated with increased mortality risk in several studies (13,17,18). Our results show that a postsurgical cause for AKI was associated with a lower risk. This is congruent with an Australian study in which patients who came from various surgical units had lower odds for hospital mortality (14). This would also be in agreement with the lower overall ICU mortality reported by Kuitenen et al. (10) in their cardiac surgery patients. Prerenal azotemia is traditionally regarded as a less problematic form of AKI. It is interesting that patients with a prerenal cause of AKI seem to have a mortality similar to those with other causes of AKI, although we may not have sufficient statistical power to detect a small difference. Although serum creatinine levels and urine output at AKI diagnosis are the basis of the RIFLE classification, they remain as independent predictor variables for mortality when placed in a multivariable analysis with RIFLE. Low urine output and anuria have been long known to be associated with poor outcomes (1,19,20). In our analysis, lower creatinine concentrations at the time of AKI diagnosis were associated with an increased risk for death. Other authors have also noted a similar pattern in their cohorts (1921). They hypothesized that low serum creatinine, particularly after adjustment for age and gender, probably reflects loss of muscle mass. However, it could also be related to volume overload and its diluting effect on the serum creatinine. Previous studies have reported the association between volume overload and mortality, in both adults and children (22,23). We also noted that a previous exposure to nephrotoxic agents was associated with a lower risk for death. One possible explanation for this favorable prognosis is that it is a readily reversible cause of AKI, and definitive management (i.e., withdrawal of the offending agent) is relatively simple to carry out.
In our study, the use of CRRT was high, particularly with respect to the practice in the United States as reported by the Program to Improve Care in Acute Renal Disease (PICARD) study (24). The reason for the difference in center practices is not clear. We found that a collaborative effort between the nephrologist and the intensivist, as well as the ICU and dialysis nurse (data not shown), predominates among our centers, which may differ from the practices in "closed" ICU systems (25).
In our analysis, the serum creatinine criteria of the classification seemed to be a better predictor of mortality than urine output. However, the very wide CI suggest an unstable statistical model that should be interpreted with caution, which may in part be related to the relatively small number of patients in the Io category. A rise in serum creatinine is an earlier sign of worsening renal function than oliguria. In >50% of our patients with AKI, the creatinine criteria led to a worse RIFLE class than urine output. That the predictive value of the "true" RIFLE class (using both creatinine and urine output criteria) was statistically more stable underlines the clinical utility of using the composite criteria to define the wide range of disease spectra in AKI.
The results of our study support the utility of the RIFLE classification in prognosticating the outcome of patients with AKI. The study included a large cohort of patients from multiple centers, using both serum creatinine and urine output criteria, as was intended by ADQI. To our knowledge, this is the first prospective, multicenter evaluation of the RIFLE classification and the first to evaluate the performance of the creatinine and urine output criteria. We acknowledge that there are several limitations to the data presented here. First, we had a predominantly white population, and our findings may not be applicable to more culturally diverse centers. Because of the study design, we were unable to compare directly patients with and without AKI. However, we were able to compare basic demographics and outcomes, such as ICU mortality and length of stay, between patients with AKI and the ICU population as a whole. We also did not include severity of illness scores in our evaluation. There was a need to assume a baseline creatinine value using the Modification of Diet in Renal Disease (MDRD) equation in patients in whom this value was not known. This assumption can obviously lead to misclassification of some patients. However, a true baseline is often unknown for many patients who are admitted to the ICU (13). The ADQI Committee was well aware of this contingency, and for this reason, they sought to develop a standardized rule for assuming the level of baseline renal function (9). Patient outcome in our study was evaluated at exit from the ICU, which underestimates the impact of AKI on outcome. Bell et al. (11) showed a difference of 19.8% between ICU and 2-mo mortality and 25.1% between ICU and 6-mo mortality. Last, because changes in serum creatinine and urine output lag behind real-time changes in renal function, there are some limits to the utility of the RIFLE classification, although it represents a tool that was hitherto unavailable. Ultimately, serum and urine biomarkers will redefine how we classify, treat, and monitor AKI.
| Conclusion |
|---|
|
|
|---|
| Disclosures |
|---|
|
|
|---|
| Acknowledgments |
|---|
Participating Centers and Investigators: Drs. Vincenzo Mione and Dario Carmelo Tomasello (Azienda Ospedaliera Santa Maria degli Angeli, Pordenone); Prof. Giorgio Della Rocca (Policlinico Universitario di Udine); Dr. Orlando Margarit (Azienda Ospedaliera Santa Maria della Misericordia, Udine); Dr. Luciano Silvestri (Ospedale di Gorizia, Gorizia); Dr. Lamberto Padovan (Ospedale Civile di Adria, Rovigo); Drs. Antonio Vassalli and Roberto Ferrari (Presidio Ospedaliero di Bassano del Grappa, Vicenza); Drs. Giorgio Zanardo and Maurizio Pegoraro (Presidio Ospedaliero di Castelfranco Veneto, Treviso); Dr. Livio Todesco (Presidio Ospedaliero di Cittadella, Padova); Dr. Antonio Digito (Presidio Ospedaliero di Feltre, Belluno); Dr. M. Luisa Ferron (Presidio Ospedaliero di Legnago, Verona); Dr. Stefania Michelon (Presidio Ospedaliero di Venezia Terraferma Ospedale Umberto Primo, Venezia); Dr. Andrea Bianchin (Presidio Ospedaliero di Montebelluna, Treviso); Drs. Marco Baiocchi, Giuseppina Bonaccorso, Raffaele Bonato (Azienda Ospedaliera di Padova, Padova); Dr. Donato Borreggine (Presidio Ospedaliero di San Donà di Piave, Venezia); Dr. Roberto Nani (Presidio Ospedaliero di Treviso, Treviso); Prof. Aldo Luzzani and Dr. Laura Borin (Azienda Ospedaliera di Verona, Verona); Dr. Pasquale Piccinni (Presidio Ospedaliero San Bortolo di Vicenza, Vicenza).
| Footnotes |
|---|
Received October 6, 2006. Accepted February 1, 2007.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Zavada, E. Hoste, R. Cartin-Ceba, P. Calzavacca, O. Gajic, G. Clermont, R. Bellomo, J. A. Kellum, and for the AKI6 investigators A comparison of three methods to estimate baseline creatinine for RIFLE classification Nephrol. Dial. Transplant., January 25, 2010; (2010): gfp766v1 - gfp766. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. H. Endre and J. W. Pickering Outcome definitions in non-dialysis intervention and prevention trials in acute kidney injury (AKI) Nephrol. Dial. Transplant., January 1, 2010; 25(1): 107 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Pickering, C. M. Frampton, and Z. H. Endre Evaluation of Trial Outcomes in Acute Kidney Injury by Creatinine Modeling Clin. J. Am. Soc. Nephrol., November 1, 2009; 4(11): 1705 - 1715. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Bagshaw, S. Uchino, D. Cruz, R. Bellomo, H. Morimatsu, S. Morgera, M. Schetz, I. Tan, C. Bouman, E. Macedo, et al. A comparison of observed versus estimated baseline creatinine for determination of RIFLE class in patients with acute kidney injury Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2739 - 2744. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Fowler, N. K. J. Adhikari, D. C. Scales, W. L. Lee, and G. D. Rubenfeld Update in Critical Care 2007 Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 808 - 819. [Full Text] [PDF] |
||||
![]() |
Z. Ricci and C. Ronco Kidney diseases beyond nephrology: intensive care Nephrol. Dial. Transplant., March 1, 2008; 23(3): 820 - 826. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |